[ by Jessica Langholtz | Feb 11, 2010 5:23 pm | No Comment ]
Revlimid-Cyclophosphamide-Prednisone Combination May Be Highly Effective For Refractory Multiple Myeloma Patients

A new study published in the British Journal of Haematology suggests that the drug combination regimen of Revlimid (lenalidomide), cyclophosphamide, and prednisone (RCP) is highly effective in multiple myeloma patients who are refractory (not responsive) to Revlimid-dexamethasone (Decadron) treatment.

The researchers of the study had previously shown that continuous low-dose oral cyclophosphamide in combination with prednisone was effective in relapsed multiple myeloma. To further improve the efficacy of the oral regimen, they added Revlimid to the drug combination.

The clinical trial enrolled 14 multiple myeloma patients who were refractory to Revlimid and dexamethasone. Patients received…

Read the full story »
[ by Funmi Adewale | Feb 10, 2010 9:46 am | 2 Comments ]
Vertebroplasty Relieves Pain And Restores Mobility In Myeloma-Related Spinal Fractures, Study Finds

A recent study published in the journal Neurological Sciences determined that injecting bone cement into fracture sites in the spine, a procedure called vertebroplasty, leads to fast pain relief and restored mobility in multiple myeloma patients.

Myeloma cells accelerate processes that degrade bone, resulting in bone lesions and fractures. Spinal fractures, in particular, are a common complication associated with multiple myeloma and can leave patients unable to walk. Treatment options include radiation therapy, medication, and a minimally invasive procedure called vertebroplasty (for further description, see related Beacon article).

In the study, researchers looked…

Read the full story »